Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Papillary Thyroid Cancer.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback